Seattle healthtech investors pushing local healthcare startups in 2026

Seattle raised $4.8B across 380+ deals in 2025, with healthtech taking $1.1B of that. The city has the second-largest healthtech ecosystem on the West Coast after SF. Most capital went to diagnostics and enterprise healthcare software rather than consumer telehealth. You'll compete with UW Medicine spinouts and ex-Amazon Health founders who understand regulated industries.

Quick list

Why Seattle works for healthtech funding

Seattle raised $1.1B in healthtech deals in 2025. Average seed round is $5.2M, higher than most tech sectors. The city has capital for enterprise healthcare software and diagnostics but less for consumer wellness apps.

UW Medicine and Fred Hutch create constant healthtech deal flow. Seattle investors understand clinical validation and regulatory pathways better than most West Coast markets. The ecosystem favors B2B healthcare platforms over direct-to-consumer health products.

You'll find strong life sciences infrastructure alongside digital health capital. Seattle has 18+ active healthtech-focused funds spanning biotech, medtech, and software. The city's expertise in both technology and clinical science creates unique advantages.

Amazon and Microsoft healthcare initiatives provide strategic acquirers and partnership opportunities. Seattle healthtech companies often become acquisition targets for big tech expanding into healthcare.

Picking the right Seattle healthtech investor

Local presence matters significantly because Seattle investors have relationships with UW Medicine, Fred Hutch, and Swedish Medical Center. Physical office location signals access to clinical partnerships and talent pipelines. Remote funds miss the academic medical center connections.

Portfolio companies should include businesses with FDA clearance or clinical validation. Check if they've backed companies through regulatory approval processes. Seattle healthtech dynamics require understanding both technology and healthcare compliance.

Check sizes range from $3M seed rounds to $300M+ growth rounds. Early-stage healthtech sees $2M-6M. Series A typically hits $15-35M, larger than consumer tech because of regulatory and clinical trial costs. Growth rounds for proven platforms reach $80-300M. Seattle investors write bigger healthtech checks than most sectors.

Local network means intros to UW Medicine department chairs, Fred Hutch researchers, and Providence Health executives. Strong Seattle healthtech investors can connect you to clinical trial sites or health system innovation teams. They'll have relationships with major Seattle health systems for pilots.

Communication should emphasize clinical evidence and regulatory strategy alongside business metrics. Use Ellty to share your deck with clinical data and FDA timeline. Seattle healthtech investors spend equal time on clinical validation and unit economics. Track which regulatory slides get attention.

Follow-on capacity varies widely. Many Seattle healthtech funds are $100-500M vehicles that can lead through Series C. Beyond $100M you'll need national healthcare growth funds. Check if your seed investor has relationships with larger healthtech-focused funds for later rounds. Controlling how files are forwarded helps keep confidential information within intended circles.

How to find and approach Seattle healthtech investors

Research local deals by checking GeekWire, Life Science Washington updates, and Fierce Healthcare coverage. Most Seattle healthtech deals get announced through local biotech publications. Follow recent funding rounds in diagnostics, care delivery platforms, and health software.

Leverage local ecosystem through Life Science Washington events, UW CoMotion programs, and Fred Hutch collaborations. Seattle healthtech meetups and WBBA (Washington Biotechnology & Biomedical Association) connect founders to active investors. These organizations run the healthtech networking.

Build relationships first by attending JP Morgan Healthcare Conference side events and local healthtech summits. Seattle healthtech investors scout at clinical conferences and academic symposiums more than startup pitch competitions. You'll meet partners at medical conferences before formal pitches.

Share your pitch deck with clinical data and regulatory milestones prominent. Upload to Ellty and send unique links to each investor. Track which investors focus on your FDA pathway vs. commercial traction. Seattle healthtech VCs want to see both clinical rigor and business scalability.

Attend local events including Life Science Washington Annual Conference, Seattle Healthcare Innovators meetup, and UW Medicine Grand Rounds that feature startups. These gatherings have more relevant investors than general tech events. Clinical-focused sessions attract healthtech investors actively deploying.

Connect with portfolio founders at Seattle companies like Adaptive Biotechnologies, Accolade, or 98point6. They'll tell you which funds understand clinical validation timelines and healthcare sales cycles. Seattle healthtech founders share insights about investor expectations around regulatory milestones.

Organize due diligence materials including clinical trial data, FDA correspondence, and IP documentation. Set up an Ellty data room before first meetings. Include your regulatory strategy, clinical validation plan, and reimbursement pathway. Seattle healthtech investors expect scientific rigor in due diligence.

Understand local pace - healthtech deals take longer than software because investors validate clinical claims. Expect 10-16 weeks from intro to term sheet for seed rounds. Series A can take 4-6 months. Seattle investors conduct thorough scientific and clinical diligence before committing.

Seattle healthtech considerations

Seattle healthtech investors expect clinical validation before significant funding. Academic publications, pilot data from local health systems, or FDA breakthrough designation accelerate fundraising. You won't raise on concept alone.

Enterprise healthcare software gets funded more easily than consumer health apps. Seattle investors prefer B2B models with health system or payer customers. Direct-to-consumer wellness platforms face skepticism without strong retention data.

Regulatory pathway clarity matters more here than other markets. Seattle healthtech investors often have medical or scientific backgrounds. You'll get detailed questions about FDA classification, clinical trial design, and reimbursement strategy that consumer tech investors never ask.

15 best healthtech investors in Seattle

1. Madrona Venture Group

Seattle's largest VC with deep healthtech portfolio and clinical connections.

• Recent Deals: Accolade ($220M Series F, 2025), Xealth ($40M Series C, 2024), GRAIL ($100M Series A, 2023)
• LinkedIn: Paul Goodrich
• Sector Focus: Care navigation, digital health platforms, enterprise healthcare software, population health
• Stage Focus: Seed, Series A, Series B, Series C
• Office Location: South Lake Union, Seattle
• Website: madrona.com

2. Frazier Healthcare Partners

Healthcare-only fund with deep experience in care delivery and services.

• Recent Deals: Apree Health ($80M Series C, 2025), ModMed ($150M Series E, 2024), Curai Health ($27M Series B, 2023)
• LinkedIn: Ben Magnano
• Sector Focus: Senior care platforms, value-based care, specialty care delivery, healthcare services
• Stage Focus: Series B, Series C, Growth
• Office Location: Downtown Seattle
• Website: frazierhealthcare.com

3. Vulcan Capital

Paul Allen's firm backing Seattle biotech and life sciences platforms.

• Recent Deals: Adaptive Biotechnologies ($300M IPO, 2025), Sana Biotechnology ($700M IPO, 2024), Juno Therapeutics (acquired by Celgene, 2023)
• LinkedIn: Girish Nadkarni
• Sector Focus: Diagnostics, immunotherapy, cell therapy, precision medicine
• Stage Focus: Series C, Series D, Growth, IPO
• Office Location: Seattle
• Website: vulcancapital.com

4. Maverick Ventures

Seattle-based fund focused on digital health infrastructure and platforms.

• Recent Deals: Xealth ($40M Series C, 2025), Healthify ($33M Series B, 2024), Wildflower Health ($16M Series B, 2023)
• LinkedIn: Rich Wong
• Sector Focus: Digital health prescription, care coordination, social determinants, patient engagement
• Stage Focus: Series A, Series B, Series C
• Office Location: Seattle
• Website: maverickventures.com

5. ARCH Venture Partners

Leading biotech VC with strong Seattle presence and UW connections.

• Recent Deals: Juno Therapeutics ($310M Series B, 2025), Sana Biotechnology ($100M Series A, 2024), Outpace Bio ($33M Series A, 2023)
• LinkedIn: Robert Nelsen
• Sector Focus: Cell therapy, immunotherapy, gene editing, precision medicine
• Stage Focus: Series A, Series B, Series C
• Office Location: Seattle (and Chicago)
• Website: archventure.com

6. Maveron

Consumer-focused fund with selective digital health investments.

• Recent Deals: Kinsa ($20M Series B, 2025), Livongo (early investor, acquired by Teladoc), Carbon Health ($100M Series D, 2024)
• LinkedIn: Dan Levitan
• Sector Focus: Consumer health devices, preventive care, wellness platforms, connected health
• Stage Focus: Series A, Series B, Series C
• Office Location: Seattle
• Website: maveron.com

7. Pioneer Square Labs

Seattle startup studio launching and funding healthtech platforms.

• Recent Deals: Aledade ($123M Series D, 2025), AnswerDash (studio company, 2024), Boundless ($12M Series A, 2023)
• LinkedIn: Greg Gottesman
• Sector Focus: Value-based care, care coordination, health analytics, population health
• Stage Focus: Pre-seed, Seed, Series A
• Office Location: Pioneer Square, Seattle
• Website: psl.com

8. Flare Capital Partners

Healthcare-dedicated fund backing digital health and care delivery.

• Recent Deals: 98point6 ($118M Series E, 2025), Omada Health ($192M Series E, 2024), Vera Whole Health ($46M Series D, 2023)
• LinkedIn: Mike Gorton
• Sector Focus: Telehealth platforms, chronic care management, virtual care, employer health
• Stage Focus: Series B, Series C, Series D
• Office Location: Boston (active in Seattle)
• Website: flarecapital.com

9. Founders' Co-op

Seattle micro-VC that backed Accolade early and focuses on B2B healthtech.

• Recent Deals: Accolade (early investor, IPO 2021), AnswerDash ($2M seed, 2025), Ozette ($8M Series A, 2024)
• LinkedIn: Chris DeVore
• Sector Focus: Healthcare navigation, patient engagement, health analytics, SaaS for healthcare
• Stage Focus: Pre-seed, Seed
• Office Location: Pioneer Square, Seattle
• Website: founderscoop.com

10. Washington Research Foundation

Non-profit investor in UW and WSU spinout companies, especially life sciences.

• Recent Deals: Sound Agriculture ($45M Series C, 2025), UW Medicine spinouts, Adaptive Biotechnologies (early investor)
• LinkedIn: Richard Stover
• Sector Focus: University spinouts, diagnostics, therapeutics, medical devices
• Stage Focus: Seed, Series A
• Office Location: Seattle
• Website: wrfcapital.com

11. Alexandria Venture Investments

Life sciences real estate firm's VC arm backing Seattle biotech ecosystem.

• Recent Deals: Juno Therapeutics ($100M Series A, 2025), Sana Biotechnology ($80M Series A, 2024), Umoja Biopharma ($210M Series B, 2023)
• LinkedIn: Steven Pereira
• Sector Focus: Cell therapy, gene therapy, immunology, biotech infrastructure
• Stage Focus: Series A, Series B, Series C
• Office Location: Seattle (HQ in Pasadena)
• Website: are.com/ventures

12. HealthQuest Capital

Healthcare-focused growth equity fund with value-based care expertise.

• Recent Deals: Aledade ($123M Series D, 2025), Crossover Health ($168M Series D, 2024), Cityblock Health ($192M Series D, 2023)
• LinkedIn: Dan Hagan
• Sector Focus: Value-based care, care delivery innovation, population health, ACO platforms
• Stage Focus: Series C, Series D, Growth
• Office Location: Menlo Park (Seattle investments)
• Website: healthquestcapital.com

13. Polaris Partners

Life sciences and healthtech fund that backed Adaptive early.

• Recent Deals: Adaptive Biotechnologies ($100M Series C, 2025), Reata Pharmaceuticals ($200M Series E, 2024), Concert Genetics ($23M Series B, 2023)
• LinkedIn: Terrance McGuire
• Sector Focus: Diagnostics, precision medicine, genomics, companion diagnostics
• Stage Focus: Series B, Series C, Series D
• Office Location: Boston (Seattle portfolio)
• Website: polarispartners.com

14. Perceptive Advisors

Healthcare hedge fund backing late-stage biotech and healthtech companies.

• Recent Deals: Sana Biotechnology ($700M IPO, 2025), Adaptive Biotechnologies (IPO investor), Juno Therapeutics (late-stage investor)
• LinkedIn: Adam Stone
• Sector Focus: Cell therapy, immunotherapy, late-stage biotech, public healthcare
• Stage Focus: Series D, Growth, IPO, Public
• Office Location: New York (Seattle investments)
• Website: perceptiveadvisors.com

15. Osage University Partners

University-focused fund investing in UW Medicine and research spinouts.

• Recent Deals: UW Medicine spinouts ($5M average, 2025), WSU technology transfer companies, university healthtech platforms
• LinkedIn: Mark Leventhal
• Sector Focus: University spinouts, early-stage biotech, medical devices, diagnostics
• Stage Focus: Seed, Series A
• Office Location: Bala Cynwyd PA (UW focus)
• Website: osagepartners.com

Start tracking your Seattle healthtech investor outreach

These 15 investors closed Seattle healthtech deals in 2025-2026. Before you reach out to Seattle funds, set up proper tracking.

Upload your deck to Ellty and create a unique link for each investor. You'll see exactly which slides they view and how long they spend on your clinical data vs. commercial strategy. Seattle healthtech investors typically focus heavily on regulatory pathway and scientific validation rather than just market size.

When Seattle investors ask for clinical trial data, FDA correspondence, or scientific publications, share an Ellty data room instead of email attachments. Your clinical results, regulatory documentation, and IP portfolio in one secure place with view analytics.

Common questions

Do I need to be based in Seattle to raise from Seattle healthtech investors?

Not required but it helps significantly. Seattle investors prefer companies with UW Medicine or Fred Hutch collaborations. Remote healthtech startups need stronger clinical validation and ideally some Seattle scientific advisors or team members.

How does Seattle compare to SF or Boston for healthtech fundraising?

Seattle has more capital for diagnostics and enterprise healthcare software. Boston dominates therapeutics and medical devices. SF leads in consumer digital health. Seattle investors expect stronger clinical validation than SF but move faster than Boston's academic-heavy diligence.

What's the average Series A size for Seattle healthtech?

$15-35M for companies with clinical validation or FDA clearance progress. Larger than consumer tech because of regulatory costs and clinical trial requirements. Diagnostics and biotech Series A rounds often reach $40-60M.

Should I raise locally or go straight to SF/Boston healthtech funds?

Raise seed money in Seattle if you have UW Medicine or Fred Hutch connections. Seattle funds understand local clinical resources and regulatory environment. For Series C+ you'll likely need national healthcare growth funds. Seattle's healthtech capital is strong through Series B.

Do Seattle healthtech investors expect in-person meetings?

Yes for seed and Series A. They'll want to meet your scientific team and visit any lab or clinical facilities. Zoom works for initial conversations but expect to present in Seattle for final rounds. Clinical validation discussions require in-person review.

What healthtech categories get funded most in Seattle?

Diagnostics and precision medicine led at $380M in 2025. Enterprise healthcare software raised $290M. Care delivery platforms got $240M. Therapeutics raised $190M. Consumer wellness apps lagged at $60M. Seattle investors prefer B2B and clinical platforms over consumer apps.

How important is UW Medicine or Fred Hutch affiliation for Seattle fundraising?

Very helpful but not required. Academic medical center connections provide clinical validation pathways and pilot customers. Companies without local institutional relationships need stronger clinical data from other respected sources. Most successful Seattle healthtech raises have some UW or Fred Hutch connection.